Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Farmers Insurance
Harvard Business School
Teva
McKesson
AstraZeneca

Generated: September 15, 2019

DrugPatentWatch Database Preview

Patent: 9,546,353

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,546,353
Title:Optimized and defined method for isolation and preservation of precursor cells from human umbilical cord
Abstract: The present invention refers to an optimized and defined method for isolation and preservation of precursor cells from human umbilical cord. Besides being reproducible and 100% reliable, in terms of the number of samples processed, the method results in a high and defined number of precursor cells, being the majority obtained after a single adhesion and expansion/multiplication phase ex vivo (thus granting cell phenotype), in a shorter time frame than what was previously described in the state-of-the-art. With this method, it is possible to obtain, in 9 days, after direct freezing of a cell fraction, and after one expansion/multiplication phase ex vivo (end of P0) of the majority of the cells, about 8.6(.+-.0.1).times.10.sup.5 cells/gram of processed umbilical cord. In turn, the characteristics of the cells allow, for example, after 35 days, obtaining an average of 7.7.times.10.sup.15 cells, with precursor phenotype, from 100% of processed umbilical cord samples. The method, because it is simple, robust and 100% reliable, can be performed under good manufacturing practices (GMP) in laboratories dedicated to cell therapy in humans. Furthermore, the method has applications in the pharmaceutical, cosmetic and biotechnology areas.
Inventor(s): Ganchas Soares; Rita Isabel (Oeiras, PT), Baptista Coelho; Maria Constanca (Oeiras, PT), Silva Santos; Jorge Miguel (Oeiras, PT), Martins; Jose Paulo (Oeiras, PT), Basto; Vera Alexandra (Oeiras, PT), Estilita Monteiro Da Cruz; Pedro (Oeiras, PT), Soares Da Cruz; Helder Joaquim (Oeiras, PT)
Assignee: Laboratorio Medinfar-Produtos Farmaceuticos, S.A. (Amadora, PT)
Application Number:12/680,604
Patent Claims:see list of patent claims

Details for Patent 9,546,353

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Advance Biofactures SANTYL collagenase VIAL 101995 001 1965-06-04 ➤ Sign Up Laboratorio Medinfar-Produtos Farmaceuticos, S.A. (Amadora, PT) 2027-10-04 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Fuji
Federal Trade Commission
McKinsey
Argus Health
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.